drugset / Trial / NCT01360593
Gemcitabine/Capecitabine Followed by SBRT in Pancreatic Adenocarcinoma
NaSingle-groupOpen-labelTreatment
Summary
The current study seeks to further investigate the impact of up-front systemic therapy in combination with fractionated SBRT for potentially resectable, locally-advanced pancreatic adenocarcinoma.
Timeline
- Start
- 2011-07-25
- Primary completion
- 2016-03-13
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capecitabine | Small molecule | 650 mg/m2 | Oral |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |